Nicklaus Children's Hospital achieves Stage 7

HIMSS Analytics has awarded Nicklaus Children’s Hospital in Miami with a Stage 7 Award, the highest level on the Electronic Medical Record Adoption Model (EMRAM).

HIMSS Analytics developed the EMR Adoption Model in 2005 as a methodology for evaluating the progress and impact of EMR systems for hospitals in the HIMSS Analytics Logic. Stage 7 represents an advanced patient record environment.

During the fourth quarter of 2015, only 4.2 percent of the more than 5,400 U.S. hospitals in the HIMSS Analytics Logic received the Stage 7 Award.

“Very early on in this journey we saw the importance that digitization places on the patients and families in our care, from reducing costs, improving care and improving the service to our customers. We are honored to be recognized for our ability to adopt and embrace a digitized healthcare workplace,” said Edward Martinez, senior vice president and CIO at Miami Children’s Health System, in a release.

Founded in 1950 by Variety Clubs International, Nicklaus Children’s Hospital, part of Miami Children’s Health System, is South Florida’s only licensed specialty hospital exclusively for children, with more than 650 attending physicians and over 130 pediatric sub-specialists.

The Nicklaus Children’s Hospital will be recognized at the 2017 Annual HIMSS Conference & Exhibition next February in Orlando.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

CMS finalized a significant policy change when it increased the Medicare payments hospitals receive for performing CCTA exams. What, exactly, does the update mean for cardiologists, billing specialists and other hospital employees?

Stryker, a global medtech company based out of Michigan, has kicked off 2025 with a bit of excitement. The company says Inari’s peripheral vascular portfolio is highly complementary to its own neurovascular portfolio.

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.